Fenugreek vs Melanotan Ii for libido
Short answer: For libido, users rate them about the same: 100% report improvement with Fenugreek (19 reports) and 96% with Melanotan Ii (48 reports).
Fenugreek has 33 meta-analyses and 45 randomized trials on PubMed; Melanotan Ii has 1 and 1.
Based on 132 reports about Fenugreek and 186 about Melanotan Ii. Not medical advice.
| Fenugreek Supplement | Melanotan Ii Peptide | |
|---|---|---|
| Users say it helped | 63%helped42 reports · medium confidence | 60%helped115 reports · high confidence |
| Verdict | Mostly positive | Mixed |
| Research | AResearch: Strong | BResearch: Moderate |
| Meta-analyses / RCTs | 33 / 45 | 1 / 1 |
| Mainly used for | ||
| Skin & hair % reporting improvement | — | 88% (84) |
| Libido % reporting improvement | 100% (19) | 96% (48) |
| Hormones % reporting improvement | 78% (18) | — |
| Weight loss % reporting improvement | — | 100% (12) |
| Appetite % reporting improvement | 50% (4) | 57% (7) |
| Common side effects | maple syrup, insomnia, 5-ar inhibition, body odor | nausea, flushing, freckles, moles |
| Typical dose reported | 500 mg / before bed | Not listed |
3) Food matrix effects: the addition of dietary fats and fibre increased bioavailability by ∼2-fold. This review summarises key factors that enhance quercetin bioavailability, contributing to the development of more effective and practical quercetin supplements or functional foods for better bioactivity of quercetin in humans.
Food Chem, 2025 ↗“The walmart stack is Zinc + Fenugreek. I think it works pretty well.”
Almost all studies are in the preclinical phase. There are currently no effective clinical treatments for MC4R-deficient obese patients, although MC4R agonists are being developed and are entering phase I and II trials.
Int J Obes (Lond), 2014 ↗“I've found that getting sun within 3-12 hours will produce the desired result.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate